Journals / Anadolu Kardiyoloji Dergisi / 2006 / Cilt: 6 - Sayı: 3

Hepcidin aterosklerozda kronik inflamasyonun bir göstergesi değildir

Hepcidin is not a marker of chronic inflammation in atherosclerosis

Pages
239–242
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: These findings did not support the hypothesis that hepcidin levels could be increased in atherosclerotic cardiovascular diseases as a marker of chronic inflammation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the relationship between atherosclerosis, an inflammatory disease and hepcidin which is reported as an indicator of inflammation Methods: A total of 75 subjects between 40 and 70 years of age were included in the study.
📊
Key Findings & Data:The patient group consisted of 40 stable patients who had previously experienced an atherosclerotic event (18 women, 22 men; mean age 56.4±7.1 years).
💡
Conclusion & Impact:Conclusion: These findings did not support the hypothesis that hepcidin levels could be increased in atherosclerotic cardiovascular diseases as a marker of chronic inflammation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the relationship between atherosclerosis, an inflammatory disease and hepcidin which is reported as an indicator of inflammation Methods: A total of 75 subjects between 40 and 70 years of age were included in the study. The patient group consisted of 40 stable patients who had previously experienced an atherosclerotic event (18 women, 22 men; mean age 56.4±7.1 years). There were two control groups. The first control group consisted of 19 healthy subjects (11 women, 8 men; mean age 52.6± 7.4 years), while the second group included 16 patients (11 women, 5 men; mean age 56.5±9.3 years) with rheumatoid arthritis and anemia (diseased control group). Hepcidin measurement was performed using Hepcidin Prohormone ELISA (Solid Phase Enzyme-Linked Immunosorbent Assay) test kit. Results: Mean serum hepcidin levels were 243.2±48.8 ng/ml, 374.5±86.4 ng/ml, and 234±59.9 ng/ml in the patient group, in diseased controls, and in healthy controls, respectively. Hepcidin levels were higher in diseased controls compared to the patient group and healthy controls (p=0.001). There were no significant differences between the patient group and healthy controls. Conclusion: These findings did not support the hypothesis that hepcidin levels could be increased in atherosclerotic cardiovascular diseases as a marker of chronic inflammation.

Özet

Amaç: Kronik inflamatuvar bir hastalık olan ateroskleroz ile inflamatuvar bir belirteç olduğu bildirilen hepcidin arasındaki ilişkiyi araştırmak. Yöntemler: Çalışmaya 40 ve 70 yaş arası toplam 75 olgu alındı. Hasta grubu aterosklerotik bir olay geçirmiş ve stabil olan 40 hastadan (18 kadın, 22 erkek; ortalama yaş 56.4±7.1 yıl) oluştu. İki kontrol grubu alındı. Birinci kontrol grubu 19 kişiden oluşan sağlıklı kontrol grubu idi (11 kadın, 8 erkek, ortalama yaş: 52.6± 7.4 yıl). İkinci kontrol grubu hastalıklı kontrol grubu idi. Burada romatoid artrit ve anemisi olan 16 hasta (11 kadın, 5 erkek, ortalama yaş: 56.5±9.3 yıl) vardı. Hepcidin ölçümü Hepcidin Prohormone ELISA (Solid Phase Enzyme-Linked Immunosorbent Assay) test kit’i kullanılarak yapıldı. Bulgular: Ortalama serum hepcidin düzeyleri hasta, hastalıklı kontrol ve sağlıklı kontrol gruplarında sırasıyla 243.2±48.8 ng/ml, 374.5±86.4 ng/ml ve 234±59.9 ng/ml idi. Hastalıklı kontrol grubunun hepcidin düzeyleri hasta grubu ve sağlıklı kontrol grubuna göre yüksekti (p= 0.001). Hasta grubu ve sağlıklı kontrol grupları arasında anlamlı fark yoktu. Sonuç: Bu bulgular kronik inflamasyonun bir göstergesi olarak hepcidin düzeylerinin, aterosklerotik kardiyovasküler hastalıklarda yüksek bulunabileceği hipotezini desteklemedi.

🔖

Cite This Article

UZUNLULU, M., OĞUZ, A., HEKİM, N. (2022). Hepcidin aterosklerozda kronik inflamasyonun bir göstergesi değildir. Anadolu Kardiyoloji Dergisi, Cilt: 6 - Sayı: 3, 239–242. https://ajindex.com/articles/437268

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26
  2. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999; 341: 1986-95
  3. Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis 2003; 41 (Suppl 1):S80-3
  4. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-8
  5. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-10
  6. Deicher R, Hörl WH. Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial Transplant 2004; 19: 521-4
  7. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gen encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-44
  8. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-6
  9. WHO Scientific Group. Nutritional anaemias. Geneva: World Health Organization; 1968, 10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
  10. Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, et al. Pro-hepcidin: expression and cell-specific localization in the liver and its regulation in hereditary hemochromatosis, chronic renal insufficiency, and renal anemia. GUT 2004; 53: 735-43
  11. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly-disulfide bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 147-50
  12. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Clin Res 2001; 89: 763-71
  13. Acarturk E. C-reactive protein and coronary artery disease. Anadolu Kardiyol Derg 2004; 4: 203-4
  14. Turkoglu EI, Gurgun C, Zoghi M, Turkoglu C. The relationship between serum C-reactive protein levels and coronary artery disease in patients with stable angina pectoris and positive exercise stress test. Anadolu Kardiyol Derg 2004; 4: 199-202
  15. Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 2004; 116 (Suppl 7A): S50-7
  16. Weiss G, Goodnough LT. Anemia of